NO320356B1 - Fremgangsmate for fremstilling av et matrikstype-medisinsk forlenget-frigjoring granulaert preparater - Google Patents

Fremgangsmate for fremstilling av et matrikstype-medisinsk forlenget-frigjoring granulaert preparater Download PDF

Info

Publication number: NO320356B1
Authority: NO; Norway
Prior art keywords: polymer; plasticizer; granules; temperature; extended
Prior art date: 1994-12-19

Application number

NO19972814A

Other languages

English (en)

Norwegian (no)

Other versions

NO972814L (no

NO972814D0 (no

Inventor

Niroaki Nakagami

Masazumi Kojima

Shinji Sagasaki

Original Assignee

Daiichi Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-19

Filing date

1997-06-18

Publication date

2005-11-28

1997-06-18 Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co

1997-06-18 Publication of NO972814D0 publication Critical patent/NO972814D0/no

1997-08-18 Publication of NO972814L publication Critical patent/NO972814L/no

2005-11-28 Publication of NO320356B1 publication Critical patent/NO320356B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 89
238000000034 method Methods 0.000 title claims abstract description 47
239000000203 mixture Substances 0.000 title claims abstract description 37
238000013265 extended release Methods 0.000 title claims description 43
238000009472 formulation Methods 0.000 title description 9
239000011159 matrix material Substances 0.000 title description 5
239000008187 granular material Substances 0.000 claims abstract description 71
229920000642 polymer Polymers 0.000 claims abstract description 68
239000002245 particle Substances 0.000 claims abstract description 42
239000004014 plasticizer Substances 0.000 claims abstract description 35
239000004615 ingredient Substances 0.000 claims abstract description 28
230000009477 glass transition Effects 0.000 claims abstract description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
239000000725 suspension Substances 0.000 claims description 17
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
-1 alkyl citrate Chemical compound 0.000 claims description 11
239000001856 Ethyl cellulose Substances 0.000 claims description 10
235000019325 ethyl cellulose Nutrition 0.000 claims description 10
229920001249 ethyl cellulose Polymers 0.000 claims description 10
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical group CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
239000000194 fatty acid Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 4
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 4
229920001223 polyethylene glycol Polymers 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 10
238000013268 sustained release Methods 0.000 abstract description 6
239000012730 sustained-release form Substances 0.000 abstract description 6
239000007900 aqueous suspension Substances 0.000 abstract description 3
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 18
238000007922 dissolution test Methods 0.000 description 17
238000005469 granulation Methods 0.000 description 15
230000003179 granulation Effects 0.000 description 14
238000001035 drying Methods 0.000 description 12
239000011230 binding agent Substances 0.000 description 11
239000004816 latex Substances 0.000 description 10
229920000126 latex Polymers 0.000 description 10
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
239000002994 raw material Substances 0.000 description 9
229960000278 theophylline Drugs 0.000 description 9
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 8
238000003756 stirring Methods 0.000 description 8
239000001069 triethyl citrate Substances 0.000 description 8
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 8
235000013769 triethyl citrate Nutrition 0.000 description 8
238000001125 extrusion Methods 0.000 description 7
238000011835 investigation Methods 0.000 description 7
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
229940068968 polysorbate 80 Drugs 0.000 description 7
229920000053 polysorbate 80 Polymers 0.000 description 7
239000000314 lubricant Substances 0.000 description 6
229960003511 macrogol Drugs 0.000 description 6
238000002156 mixing Methods 0.000 description 6
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
235000010724 Wisteria floribunda Nutrition 0.000 description 5
238000000576 coating method Methods 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
238000009775 high-speed stirring Methods 0.000 description 5
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 4
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
239000001863 hydroxypropyl cellulose Substances 0.000 description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
238000009481 moist granulation Methods 0.000 description 4
229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
239000008112 carboxymethyl-cellulose Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000001816 cooling Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000001087 glyceryl triacetate Substances 0.000 description 3
235000013773 glyceryl triacetate Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 3
239000007788 liquid Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
229940117841 methacrylic acid copolymer Drugs 0.000 description 3
229920003145 methacrylic acid copolymer Polymers 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229960002622 triacetin Drugs 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000000889 atomisation Methods 0.000 description 2
239000000227 bioadhesive Substances 0.000 description 2
230000036765 blood level Effects 0.000 description 2
238000005537 brownian motion Methods 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920000223 polyglycerol Polymers 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
238000005096 rolling process Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
230000007704 transition Effects 0.000 description 2
WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
GOJCZVPJCKEBQV-UHFFFAOYSA-N Butyl phthalyl butylglycolate Chemical compound CCCCOC(=O)COC(=O)C1=CC=CC=C1C(=O)OCCCC GOJCZVPJCKEBQV-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
206010060904 Freezing phenomenon Diseases 0.000 description 1
GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241001479493 Sousa Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
229920003054 adipate polyester Polymers 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
244000309464 bull Species 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
150000001782 cephems Chemical class 0.000 description 1
FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
229950009533 cetraxate Drugs 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000012812 general test Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000007794 irritation Effects 0.000 description 1
238000004898 kneading Methods 0.000 description 1
229960003376 levofloxacin Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960003253 procainamide hydrochloride Drugs 0.000 description 1
ABTXGJFUQRCPNH-UHFFFAOYSA-N procainamide hydrochloride Chemical compound [H+].[Cl-].CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 ABTXGJFUQRCPNH-UHFFFAOYSA-N 0.000 description 1
238000012545 processing Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229920002050 silicone resin Polymers 0.000 description 1
239000002002 slurry Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013526 supercooled liquid Substances 0.000 description 1
MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 description 1
229960002961 ticlopidine hydrochloride Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
229960000401 tranexamic acid Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
238000010977 unit operation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO19972814A 1994-12-19 1997-06-18 Fremgangsmate for fremstilling av et matrikstype-medisinsk forlenget-frigjoring granulaert preparater NO320356B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP31441494		1994-12-19
PCT/JP1995/002594 WO1996019200A1 (en)	1994-12-19	1995-12-18	Sustained-release granular preparation and process for producing the same

Publications (3)

Publication Number	Publication Date
NO972814D0 NO972814D0 (no)	1997-06-18
NO972814L NO972814L (no)	1997-08-18
NO320356B1 true NO320356B1 (no)	2005-11-28

Family

ID=18053063

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19972814A NO320356B1 (no)	1994-12-19	1997-06-18	Fremgangsmate for fremstilling av et matrikstype-medisinsk forlenget-frigjoring granulaert preparater

Country Status (14)

Country	Link
US (2)	US5858411A (de)
EP (1)	EP0797987B1 (de)
JP (1)	JP3893439B2 (de)
KR (1)	KR100424931B1 (de)
CN (1)	CN1093758C (de)
AT (1)	ATE251896T1 (de)
DE (1)	DE69531957T2 (de)
DK (1)	DK0797987T3 (de)
ES (1)	ES2210321T3 (de)
FI (1)	FI119720B (de)
NO (1)	NO320356B1 (de)
PT (1)	PT797987E (de)
TW (1)	TW406022B (de)
WO (1)	WO1996019200A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6524832B1 (en)	1994-02-04	2003-02-25	Arch Development Corporation	DNA damaging agents in combination with tyrosine kinase inhibitors
PT901786E (pt)	1997-08-11	2007-08-07	Pfizer Prod Inc	Disperções farmacêuticas sólidas com biodisponibilidade melhorada
US6632455B2 (en) *	1997-12-22	2003-10-14	Schering Corporation	Molecular dispersion composition with enhanced bioavailability
DE19820801A1 (de) *	1998-05-09	1999-11-25	Gruenenthal Gmbh	Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
US6579953B1 (en)	1998-09-30	2003-06-17	Basf Aktiengesellschaft	Application of water-soluble or water-dispersible polymerizates which contain poly-ether and which are used as a coating agent, a binding agent and/or as a film-forming auxiliary agent in pharmaceutical forms of administration
EP1027885B1 (de) *	1999-02-09	2008-07-09	Pfizer Products Inc.	Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US6316462B1 (en)	1999-04-09	2001-11-13	Schering Corporation	Methods of inducing cancer cell death and tumor regression
GB0003782D0 (en) *	2000-02-17	2000-04-05	Dumex Ltd As	Process
JP4310605B2 (ja) *	2001-05-25	2009-08-12	大塚製薬株式会社	医薬用組成物
US20090214644A1 (en) *	2003-07-31	2009-08-27	Xanodyne Pharmaceuticals, Inc.	Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) *	2003-07-31	2005-02-03	Xanodyne Pharmacal, Inc.	Tranexamic acid formulations with reduced adverse effects
US20050244495A1 (en) *	2004-03-04	2005-11-03	Xanodyne Pharmaceuticals, Inc.	Tranexamic acid formulations
US20050245614A1 (en) *	2004-03-04	2005-11-03	Xanodyne Pharmaceuticals, Inc.	Tranexamic acid formulations
US8022106B2 (en) *	2004-03-04	2011-09-20	Ferring B.V.	Tranexamic acid formulations
US20090215898A1 (en)	2004-03-04	2009-08-27	Xanodyne Pharmaceuticals, Inc.	Tranexamic acid formulations
US7947739B2 (en)	2004-03-04	2011-05-24	Ferring B.V.	Tranexamic acid formulations
JP5205053B2 (ja) *	2004-07-30	2013-06-05	フェリングビー．ブイ．	トラネキサム酸製剤
US20070059359A1 (en) *	2005-06-07	2007-03-15	Thomas Backensfeld	Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20060275365A1 (en) *	2005-06-07	2006-12-07	Thomas Backensfeld	Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
WO2006133349A2 (en) *	2005-06-08	2006-12-14	Alpharma, Inc.	Orally disintegrable sleep aid formulations
EP1919859B1 (de)	2005-06-20	2010-06-02	Xenoport, Inc.	Acyloxyalkylcarbamat-prodrugs von tranexansäure und anwendung
US20070036859A1 (en) *	2005-08-11	2007-02-15	Perry Ronald L	Sustained release antihistamine and decongestant composition
DK2001445T3 (da) *	2006-03-16	2014-10-27	Euro Celtique	Farmaceutiske sfæroider
MX2008010233A (es) *	2008-03-10	2009-11-10	Eurodrug Lab B V	Composicion de liberacion modificada, que comprende doxofilina.
US20100280117A1 (en) *	2009-04-30	2010-11-04	Xanodyne Pharmaceuticals, Inc.	Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011091164A1 (en) *	2010-01-22	2011-07-28	Xenoport, Inc.	Oral dosage forms having a high loading of a tranexamic acid prodrug
WO2011102505A1 (ja) *	2010-02-22	2011-08-25	第一三共株式会社	経口用徐放性固形製剤
GB201010083D0 (en) *	2010-06-16	2010-07-21	Univ Bradford	Compositions and methods
KR102286952B1 (ko) *	2013-12-31	2021-08-09	롯데정밀화학 주식회사	입도분포가 조절된 히드록시프로필 메틸셀룰로오스 아세테이트 숙시네이트(hpmcas) 입자의 제조방법 및 hpmcas 분말
WO2017035408A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Compounds for treatment of immune and inflammatory disorders
AR106018A1 (es)	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
MX2018016046A (es)	2016-06-27	2019-05-02	Achillion Pharmaceuticals Inc	Quinazolina y compuestos indol para tratar trastornos medicos.
CA3053818A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
EP3841086B1 (de)	2018-08-20	2025-04-23	Achillion Pharmaceuticals, Inc.	Pharmazeutische zusammensetzungen zur behandlung von medizinischen störungen im zusammenhang mit komplementfaktor d
JP7443375B2 (ja)	2018-09-06	2024-03-05	アキリオンファーマシューティカルズ，インコーポレーテッド	医学的障害の治療のための大環状化合物
CN113365617B (zh)	2018-10-16	2025-12-23	乔治亚州立大学研究基金会股份有限公司	用于医学疾病治疗的一氧化碳前药
MX2021011507A (es)	2019-03-22	2021-12-15	Achillion Pharmaceuticals Inc	Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
CN114845708A (zh)	2019-12-19	2022-08-02	乔治亚州大学研究基金会	用于治疗细菌感染和增强抗生素的化合物
JP2023515073A (ja)	2020-02-20	2023-04-12	アキリオンファーマシューティカルズ，インコーポレーテッド	補体因子ｄ媒介障害の処置用のヘテロアリール化合物
CA3193488A1 (en)	2020-09-23	2022-03-31	Jason Allan Wiles	Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4330338A (en) *	1978-10-02	1982-05-18	Purdue Research Foundation	Pharmaceutical coating composition, and preparation and dosages so coated
US4329451A (en) *	1980-11-03	1982-05-11	The Dow Chemical Company	Preparing an aqueous dispersion of colloidal size particles of a water-insoluble polysaccharide derivative
JPS57171428A (en) *	1981-04-13	1982-10-22	Sankyo Co Ltd	Preparation of coated solid preparation
JPS6143108A (ja) *	1984-08-03	1986-03-01	Nippon Shinyaku Co Ltd	医薬品製剤及びその製造法
LU86099A1 (fr) *	1985-09-30	1987-04-02	Pharlyse	Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
CA1334379C (en) *	1987-11-24	1995-02-14	James William Mcginity	Method for preparing a solid sustained release form of a functionally active composition
US5051261A (en) *	1987-11-24	1991-09-24	Fmc Corporation	Method for preparing a solid sustained release form of a functionally active composition
US4835188A (en) *	1987-12-08	1989-05-30	American Home Products Corporation	Spray dried ibuprofen
US4916161A (en) *	1988-10-25	1990-04-10	Bristol-Myers Squibb	Taste-masking pharmaceutical agents
US5326572A (en) *	1989-03-23	1994-07-05	Fmc Corporation	Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions
EP0421582A1 (de) *	1989-10-03	1991-04-10	Warner-Lambert Company	Kaubare sprühgetrocknete spheroide Mikrokapseln, polymerüberzogene Mikrokapseln und Verfahren zu ihrer Herstellung
JPH03232814A (ja) *	1990-02-08	1991-10-16	Shin Etsu Chem Co Ltd	徐放性錠剤の製造方法
JP2915590B2 (ja) *	1991-02-15	1999-07-05	第一製薬株式会社	マスクされた粒状物
ES2111065T5 (es) *	1991-04-16	2005-06-16	Nippon Shinyaku Company, Limited	Procedimiento para producir una dispersion solida.
DE4244466C2 (de) *	1992-12-24	1995-02-23	Pharmatech Gmbh	Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und deren Verwendung zur Herstellung von pharmazeutischen Präparaten

1995
- 1995-12-18 TW TW084113515A patent/TW406022B/zh not_active IP Right Cessation
- 1995-12-18 DK DK95940461T patent/DK0797987T3/da active
- 1995-12-18 US US08/849,457 patent/US5858411A/en not_active Expired - Lifetime
- 1995-12-18 JP JP51966196A patent/JP3893439B2/ja not_active Expired - Fee Related
- 1995-12-18 KR KR1019970703851A patent/KR100424931B1/ko not_active Expired - Fee Related
- 1995-12-18 DE DE69531957T patent/DE69531957T2/de not_active Expired - Lifetime
- 1995-12-18 CN CN95196885A patent/CN1093758C/zh not_active Expired - Fee Related
- 1995-12-18 WO PCT/JP1995/002594 patent/WO1996019200A1/ja not_active Ceased
- 1995-12-18 PT PT95940461T patent/PT797987E/pt unknown
- 1995-12-18 AT AT95940461T patent/ATE251896T1/de not_active IP Right Cessation
- 1995-12-18 ES ES95940461T patent/ES2210321T3/es not_active Expired - Lifetime
- 1995-12-18 EP EP95940461A patent/EP0797987B1/de not_active Expired - Lifetime
1997
- 1997-06-18 NO NO19972814A patent/NO320356B1/no not_active IP Right Cessation
- 1997-06-18 FI FI972622A patent/FI119720B/fi active IP Right Grant
1998
- 1998-06-11 US US09/095,661 patent/US6030644A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1996019200A1 (en)	1996-06-27
FI972622A0 (fi)	1997-06-18
EP0797987A4 (de)	1998-09-09
PT797987E (pt)	2004-02-27
FI972622L (fi)	1997-06-18
NO972814L (no)	1997-08-18
EP0797987A1 (de)	1997-10-01
CN1093758C (zh)	2002-11-06
ATE251896T1 (de)	2003-11-15
DE69531957T2 (de)	2004-08-12
DE69531957D1 (de)	2003-11-20
TW406022B (en)	2000-09-21
US6030644A (en)	2000-02-29
DK0797987T3 (da)	2004-02-16
US5858411A (en)	1999-01-12
EP0797987B1 (de)	2003-10-15
FI119720B (fi)	2009-02-27
NO972814D0 (no)	1997-06-18
KR100424931B1 (ko)	2004-07-05
CN1170357A (zh)	1998-01-14
JP3893439B2 (ja)	2007-03-14
ES2210321T3 (es)	2004-07-01

Legal Events

Date	Code	Title	Description
2010-07-19	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US5858411A (en)	1999-01-12	Sustained-release granular preparations and production process thereof
JPWO1996019200A1 (ja)	1997-12-22	徐放性粒状製剤およびその製造方法
CN107854435B (zh)	2019-01-22	葡萄糖激酶激活剂的口服制剂及其制备方法
US4728513A (en)	1988-03-01	Granular delayed-release form of pharmaceutically active substances
JP4436475B2 (ja)	2010-03-24	固体の経口用薬剤形のための結合剤または被覆の製造に適当な水性分散液、該水性分散液の使用および再分散性粉末
KR101122447B1 (ko)	2012-03-20	신규 제제
WO2008010524A1 (en)	2008-01-24	Process for producing spherical elementary granule containing readily water-soluble drug
KR100913281B1 (ko)	2009-08-21	서방 제제 및 그의 제조 방법
US10918630B2 (en)	2021-02-16	Delayed release pharmaceutical composition of pantoprazole and process for formulation thereof
NO341321B1 (no)	2017-10-09	Preparat for oral administrering av tamsulosin-hydroklorid og granul med kontrollert frigivelsesformulering omfattende det samme
US20040228916A1 (en)	2004-11-18	Pharmaceutical solid preparation containing a poorly soluble drug and production process thereof
JPH05255075A (ja)	1993-10-05	矯味経口組成物の製造方法
CA2757752A1 (en)	2010-10-14	Process for producing rapidly disintegrating spheroids (pellets), granules and/or mixtures thereof
JP4711478B2 (ja)	2011-06-29	味がマスクされた薬物
JPWO2002034268A1 (ja)	2004-03-04	５−アセチル−４，６−ジメチル−２−［２−［４−（２−メトキシフェニル）ピペラジニル］エチルアミノ］ピリミジン・三塩酸塩を有効成分として含有する徐放性製剤
TWI436765B (zh)	2014-05-11	用於治療ｈｃｖ感染之醫藥組合物
EP1784161B1 (de)	2008-01-02	Formulierung mit kontrollierter freisetzung enthaltend tamsulosin hydrochlorid
CA2207334C (en)	2006-08-22	Sustained-release granular preparations and production process thereof
CN108261409A (zh)	2018-07-10	一种达比加群酯的口服药物组合物及其制备方法
CN113164455B (zh)	2026-04-03	难溶性药物的固体分散体
TW202604488A (zh)	2026-02-01	包含索托克拉固體分散體之醫藥調配物及其製備方法
JPWO2003032998A1 (ja)	2005-02-03	徐放性微粒子及びその製造方法
MX2008008915A (es)	2008-09-26	Composiciones farmaceuticas que comprenden mezclas de polimeros e ingredientes activos moderadamente solubles en agua
MX2008007428A (es)	2008-09-02	Formulacion de profamarcos para el virus de la hepatitis c